Prakt. lékáren. 2020; 16(1): 17-20 | DOI: 10.36290/lek.2020.003

Psychiatric patient in community pharmacy

Ivana Tašková1,3, Kateřina Langmaierová2,3
1 Psychiatrická nemocnice Bohnice, Praha
2 Oddělení klinické farmacie KZ, a. s., Ústí nad Labem - pracoviště Teplice
3 Ústav aplikované farmacie, Farmaceutická fakulta VFU, Brno

By World Health Organization definition, health is a state of complete physical, mental, and social well-being. One area cannot be separated from another. A psychiatric patient, by the nature of his disease, may or may not respond abnormally in casual situations. To suffer by psychiatric illness, however, does not mean to have less rights. There must be chosen a special approach when dispensing medication, especially sensitive and highly ethical. The psychiatric patient is not only fragile but for the above-mentioned reasons, usually represents different dispensation case in contrast with other somatically ill patients.

Keywords: psychiatric patient, dispensation, combination therapy.

Published: March 20, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tašková I, Langmaierová K. Psychiatric patient in community pharmacy. Praktické lékárenství. 2020;16(1):17-20. doi: 10.36290/lek.2020.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hughes CM. Medication non‑adherence in the elderly: how big is the problem? Drugs Aging. 2004; 21(12): 793-811. Go to original source...
    2. Přikryl R, Kučerová H. Adherence a postoje pacientů k medikaci antipsychotiky. Psychiat. Praxi 2009; 10(4): 171-174.
    3. Semahegn A, et al. Psychotropic medication non‑adherence and associated factors among adult patients with major psychiatric disorders: a protocol for a systematic review. Syst Rev. 2018;7(1): 10. Published 2018 Jan 22. doi: 10.1186/s13643-018-0676-y. Go to original source... Go to PubMed...
    4. De Las Cuevas C, et al. Factors influencing adherence to psychopharmacological medications in psychiatric patients: a structural equation modeling approach. Patient Prefer Adherence. 2017; 11: 681-690. Published 2017 Mar 28. doi: 10.2147/PPA.S133513. Go to original source... Go to PubMed...
    5. Prabhavalkar KS, Poovanpallil NB, et Bhatt LK. Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer. Front Pharmacol. 2015; 6: 242. doi: 10.3389/fphar.2015.00242.Další literatura u autorky a na www.praktickelekarenstvi.cz Go to original source... Go to PubMed...
    6. Baldwin DS, et Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat. 2007; 3(2): 185-191. doi: 10.2147/nedt.2007. 3. 2.185 Go to original source...
    7. Květina J, Grundmann M. Farmakologické interakce. Klin Farmakol Farm. 2003; 17(1): 17-21.
    8. Češková E. Kombinace antidepresiv v léčbě deprese: doporučení a klinická praxe, Čes a slov Psychiat. 2015; 111(1): 33-36.
    9. Palanyiappan L, Insole L, Ferrier N. Combining antidepressants: a review of evidence. Advances in Psychiatric Treatment [online]. 2009, 15(2), 90-99 [cit. 2019-10-30]. doi: 10.1192/apt.bp.107.004820. ISSN 1355-5146. Dostupné z: https://www.cambridge.org/core/product/identifier/S1355514600005460/type/journal_article Go to original source...
    10. Orlova Y, Rizzoli P, Loder E. Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. JAMA neurology. 2018; 75(5), 566-572. doi: 10.1001/jamaneurol.2017.5144. Go to original source... Go to PubMed...
    11. Horn JR, Hansten PD. Triptans and SSRIs: Triptans and SSRIs. Pharmacy Times [online]. Cranbury: Pharmacy&Healthcare Communications, LLC., 2018 [cit. 2019-11-01]. Dostupné z: www.pharmacytimes.com
    12. Státní ústav pro kontrolu léčiv [online]. 2010 [cit. 2019-10-09]. Dostupné z: www.sukl.cz
    13. Sansone RA, Sansone LA. Warfarin and Antidepressants: Happiness without Hemorrhaging. Psychiatry (Edgmont). 2009; 6(7), 24-29.
    14. Nadkarni A, et al. Drug‑Drug Interactions Between Warfarin and Psychotropics: Updated Review of the Literature. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [online]. 2012, 32(10), 932-942 [cit. 2019-10-30]. DOI: 10.1002/j.1875-9114.2012.01119. ISSN 02770008. Dostupné z: http://doi.wiley.com/10.1002/j.1875-9114.2012.01119 Go to original source...
    15. Apseloff G, et al. Effect of sertraline on protein binding of warfarin, Clin Pharmacokinet. 1997; 32 Suppl 1: 37-42. Go to original source...
    16. Singh H, Dubin W, Kaur S. Drug interactions affecting clozapine levels. Journal of Psychiatric Intensive Care [online]. 2015, 11(1), 52-65 [cit. 2019-10-30]. DOI: 10.1017/S174264641300033. Dostupné z: www.medvik.cz Go to original source...
    17. Spina E, De Leon J. Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review. Basic&Clinical Pharmacology&Toxicology [online]. 2007; 100(1), 4-22 [cit. 2019-10-27]. DOI: 10.1111/j.1742-7843.2007.00017.x. ISSN 1742-7835. Dostupné z: http://doi.wiley.com/10.1111/j.1742-7843.2007.00017 Go to original source...
    18. Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second‑generation antipsychotics. Journal of Psychiatry and Neuroscience. 2003; 28(2): 99-112. Go to PubMed...
    19. Mayerova M, et al. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatric disease and treatment. 2018; 14, 1535-1543. doi:10.2147/NDT.S163839 Go to original source... Go to PubMed...
    20. Dietle A. QTc Prolongation With Antidepressants and Antipsychotics, US Pharm. 2015; 40(11): HS34-HS40.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.